Hill et al 1 and Bartlett 2 reported the first successful use of extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) in adults and neonates in 1972 and 1975, respectively. This was soon followed by a randomised controlled trial 3 showing mortality rates around 90% with both ECMO and conventional treatment in ARDS patients, dampening any enthusiasm for ECMO. The complexity of using primitive ECMO technology and higher circuit blood-flows to completely support gas exchange was a significant limitation at that time. It was soon recognised that a significant proportion of gas exchange support can be provided by the use of less damaging mechanical ventilation strategies with adjunctive use of lowflow extracorporeal techniques that are directed at carbon dioxide (CO 2 ) removal rather than oxygenation support. Gattinoni unwitnessed out-of-hospital cardiac arrest, may be considered extraordinary by many, is not supported as a strategy by any high level of evidence and ultimately did not prove of benefit. However, this case does highlight the possible expanding use of extracorporeal therapies in intensive care practice in achieving a short-term physiological target. Nevertheless, critical care physicians should also be mindful of the associated costs, the risks and benefits of using invasive therapies to achieve a physiological target and the potential ethical dilemma of offering aggressive therapy to patients who have little chance of recovery.
So, is there any hope that these newer, low-flow partial ECCO 2 R devices will be used to improve patient outcomes? A recent study 13 in patients with moderate ARDS that used arterio-venous pumpless ECCO 2 R (Interventional Lung Assist, Novalung ® GmbH, Hechingen, Germany) to facilitate ultraprotective lung ventilation did not show any difference in the number of ventilator-free days at 28 and 60 days. However, there was a significant reduction in duration of mechanical ventilation in patients with more severe ARDS (PaO 2 /FiO 2 <150) and future studies may explore this further. Veno-venous ECCO 2 R is obviously more appealing because of its ease of use and possibly has less mechanical complications due to the avoidance of arterial cannulation. Despite the claim that the newer veno-venous ECCO 2 R devices require less intense anticoagulation, the risk of cannula and/or membrane thrombosis cannot be underestimated 14 . The devices currently available or being developed for ECCO 2 R 15 are usually classified by their ability to provide partial or complete respiratory support and are summarised in Table 1 . Unlike oxygen, which displays sigmoidal saturation kinetics to the carrier haemoglobin, most CO 2 is transported as dissolved bicarbonate and exhibits linear kinetics without saturation
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. CO 2 also diffuses rapidly across extracorporeal membranes, allowing efficient removal even at blood-flows <1 l/minute. In contrast, bloodflows in the order of 60 to 70% of patients' cardiac output may be required for complete respiratory support during veno-venous ECMO. Newer ECCO 2 R devices allow much lower blood-flows (400 to 600 ml/minute), enabling the use of a single dual-lumen catheter that can combine continuous renal replacement therapy with CO 2 removal
. The current clinical experience with these veno-venous ECCO 2 R devices is, however, limited to individual case reports, case series and animal studies. Other potential applications for ECCO 2 R that merit further investigation include partial respiratory support for acute exacerbations of chronic airways disease and bridging selected patients with chronic lung disease to lung transplantation.
Even though definitive evidence for their routine use is lacking, we may be on the cusp of a paradigm shift in using ECMO and ECCO 2 R in the management of severe respiratory failure. While measurable short-term and long-term outcome benefit need to be demonstrated to justify wider uptake of extracorporeal respiratory support, appropriately powered, randomised controlled trials may take years to complete. Standardisation of technology and its clinical application, global collaboration and minimisation of diversity in other aspects of intensive care unit care are necessary prerequisites to the design of a clinical trial that intends to rigorously test extracorporeal respiratory support in the new era.
Future studies should identify subgroups of patients with severe respiratory failure who are most likely to benefit from extracorporeal support. Qualitative outcomes and parallel economic assessment should be of high priority and investigators should ensure long-term follow-up of survivors. Apart from evidence and science, areas such as cost-effectiveness, ethics, governance, quality control and benchmarking, education, prompt and accurate reporting, creation of databases that reflect the changing demography and technology, accreditation and credentialling all need to be simultaneously addressed at a global and local level. The recently formed Asia-Pacific Chapter of the Extracorporeal Life Support Organization in collaboration with the global Extracorporeal Life Support Organization and other regional organisations will play a key role in ensuring many of these facets of extracorporeal support are addressed in the region. With time, we may eventually witness some meaningful comparisons made between conventional and extracorporeal respiratory support techniques. Until then, ECCO 2 R should remain used only as a rescue therapy for highly selected patients.
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